



Short profile

Alpha TAU Medical

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

Medical field	Oncology
Product	Alpha DaRT, Medical Devices/Immunotherapy, Alpha Particles Radiation Therapy at home, Treatment for solid tumors
Growth stage	Proof of Concept
Team	Uzi Sofer (CEO, Chairman), Ronen Segal (CTO), Robert Den (CMO), Prof. Itzhak Kelson (Chief Physics Officer), Prof. Yona Keisari (Chief Scientific Officer), Raphi Levy (Chief Financial Officer), Amnon Gat (COO)

Description of product:

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is a **novel** technology that for the first time enables the use of Alpha particles for radiation treatment of **solid tumors** in a very **safe and effective** way. Alpha DaRT also has a strong **immune stimulatory effect**, which could be combined with immunotherapy for enhanced systemic effect for treatment of cancer **metastasis**. The treatment requires only **one clinic visit** (implantation of the radiation seeds) with radiation therapy duration of **15 days**.

Project goal:

We expect to have a very meaningful **research and clinical collaboration** with leading groups and to be able to jointly validate the efficacy and safety of the use of Alpha DaRT in **new indications** and **combinational protocols** with existing treatments like immuno-therapies. Goals include introduction of new types of therapies for a vast patient population (home-based treatment, reimbursement by insurance companies) and significant improvement in patients' **quality of life**.

Project type:

As we are expecting to receive our first **CE Mark** for treatment of solid tumors in the EU, based on our first-in-human very successful clinical trial, we see of high importance the collaboration with **research and clinical teams at Charité**, as a leading European institute. Through joint collaboration by using the current clinical methods of surgery and immunotherapy in combination with Alpha DaRT, we wish to jointly develop strategy and data to enable the **adoption** of the technology in EU cancer treatment.



Eligible by the IIA



ronens@alphatau.com



Ronen Segal: +972-544-843218



www.alphatau.com

